Immunocore reports cash, equivalents of $820M as of December 31

• Immunocore (NASDAQ:IMCR) said its preliminary unaudited cash, cash equivalents and marketable securities were ~$820 million as of December 31.
• The firm said in Q4, it prepaid in full the loan outstanding under the Pharmakon loan agreement and also paid sales-related rebate accruals.

More on Immunocore

• Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
• Immunocore appoints Travis Coy as CFO
• Morgan Stanley upgrades PTC, cuts Immuneering, Amicus